Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma

Purpose. The iStent provides a direct pathway for aqueous outflow from the anterior chamber to Schlemm’s canal in patients with open-angle glaucoma (OAG). We performed a meta-analysis to evaluate the effectiveness of iStent as a standalone operation in patients with OAG in reducing the intraocular p...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu-Yen Chen, Yun-Ju Lai, Yung-Feng Yen, Li-Ying Huang
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2020/8754730
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566078241243136
author Yu-Yen Chen
Yun-Ju Lai
Yung-Feng Yen
Li-Ying Huang
author_facet Yu-Yen Chen
Yun-Ju Lai
Yung-Feng Yen
Li-Ying Huang
author_sort Yu-Yen Chen
collection DOAJ
description Purpose. The iStent provides a direct pathway for aqueous outflow from the anterior chamber to Schlemm’s canal in patients with open-angle glaucoma (OAG). We performed a meta-analysis to evaluate the effectiveness of iStent as a standalone operation in patients with OAG in reducing the intraocular pressure (IOP) and the number of topical glaucoma medications. Methods. We searched various databases between January 1, 2000, and September 30, 2019, and included only peer-reviewed, prospective, or retrospective clinical studies in our analyses. Details regarding the IOP and the number of medications at baseline and end point were recorded from each study. Standardized mean differences (SMDs) of IOP and medication numbers were calculated. Furthermore, the success rate (the proportion of IOP ≤18 mmHg and IOP reduction ≥20% at end point) and the complication rate were also summarized. Finally, a subgroup analysis was done based on the iStent generation (first and second), follow-up duration (≤6, 6–18, 18–36, and >36 months), and iStent number (one, two, and three). The outcome measures were aggregated SMDs computed from each study. Results. A total of 17 studies with 978 eyes were included in this analysis. All studies demonstrated a reduction in IOP after iStent implantation. Aggregated SMDs of IOP revealed a significant reduction (SMD = −2.64, 95% confidence interval (CI): −3.21 to −2.07). The success rate was significantly good, and most of the complication rates were low. The number of medications was also significantly reduced (SMD = −1.71, 95% CI: −2.18 to −1.24). The subgroup analysis revealed a reduction in IOP and medication burden in each category of iStent generation, follow-up duration of up to 42 months, and iStent numbers. Conclusion. Use of iStent as a standalone procedure does reduce the IOP and the number of glaucoma medications. The benefit of iStent lasts for at least 42 months.
format Article
id doaj-art-7f6f074877dd4ddcadeb9c9721c390ad
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-7f6f074877dd4ddcadeb9c9721c390ad2025-02-03T01:05:06ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/87547308754730Use of iStent as a Standalone Operation in Patients with Open-Angle GlaucomaYu-Yen Chen0Yun-Ju Lai1Yung-Feng Yen2Li-Ying Huang3School of Medicine, National Yang-Ming University, Taipei 112, TaiwanSchool of Medicine, National Yang-Ming University, Taipei 112, TaiwanSection of Infectious Diseases, Taipei City Hospital, Taipei 103, TaiwanSchool of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 242, TaiwanPurpose. The iStent provides a direct pathway for aqueous outflow from the anterior chamber to Schlemm’s canal in patients with open-angle glaucoma (OAG). We performed a meta-analysis to evaluate the effectiveness of iStent as a standalone operation in patients with OAG in reducing the intraocular pressure (IOP) and the number of topical glaucoma medications. Methods. We searched various databases between January 1, 2000, and September 30, 2019, and included only peer-reviewed, prospective, or retrospective clinical studies in our analyses. Details regarding the IOP and the number of medications at baseline and end point were recorded from each study. Standardized mean differences (SMDs) of IOP and medication numbers were calculated. Furthermore, the success rate (the proportion of IOP ≤18 mmHg and IOP reduction ≥20% at end point) and the complication rate were also summarized. Finally, a subgroup analysis was done based on the iStent generation (first and second), follow-up duration (≤6, 6–18, 18–36, and >36 months), and iStent number (one, two, and three). The outcome measures were aggregated SMDs computed from each study. Results. A total of 17 studies with 978 eyes were included in this analysis. All studies demonstrated a reduction in IOP after iStent implantation. Aggregated SMDs of IOP revealed a significant reduction (SMD = −2.64, 95% confidence interval (CI): −3.21 to −2.07). The success rate was significantly good, and most of the complication rates were low. The number of medications was also significantly reduced (SMD = −1.71, 95% CI: −2.18 to −1.24). The subgroup analysis revealed a reduction in IOP and medication burden in each category of iStent generation, follow-up duration of up to 42 months, and iStent numbers. Conclusion. Use of iStent as a standalone procedure does reduce the IOP and the number of glaucoma medications. The benefit of iStent lasts for at least 42 months.http://dx.doi.org/10.1155/2020/8754730
spellingShingle Yu-Yen Chen
Yun-Ju Lai
Yung-Feng Yen
Li-Ying Huang
Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma
Journal of Ophthalmology
title Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma
title_full Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma
title_fullStr Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma
title_full_unstemmed Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma
title_short Use of iStent as a Standalone Operation in Patients with Open-Angle Glaucoma
title_sort use of istent as a standalone operation in patients with open angle glaucoma
url http://dx.doi.org/10.1155/2020/8754730
work_keys_str_mv AT yuyenchen useofistentasastandaloneoperationinpatientswithopenangleglaucoma
AT yunjulai useofistentasastandaloneoperationinpatientswithopenangleglaucoma
AT yungfengyen useofistentasastandaloneoperationinpatientswithopenangleglaucoma
AT liyinghuang useofistentasastandaloneoperationinpatientswithopenangleglaucoma